Plaintiffs file amended complaint renewing Intron A/Temodar off-label claims in US
This article was originally published in Scrip
Executive Summary
A group of health and welfare funds, third-party payers and individual consumers have filed an amended complaint in a putative class action accusing Schering-Plough, which merged with Merck & Co, of illegally marketing Intron A (interferon alfa-2b) and Temodar (temozolomide) for off-label uses. Last year, Judge Stanley Chesler of the US District for the District of New Jersey dismissed the suit on the grounds that the plaintiffs had not provided specificity required under federal rules, but stated that the plaintiffs could file an amended complaint (scripnews.com, 28 July 2009).